Valuation: ProPhase Labs, Inc.

Market Cap 673K 584K 545K 500K 946K 64M 957K 6.42M 2.51M 31.99M 2.53M 2.47M 106M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.2M 7.99M 7.45M 6.84M 12.94M 875M 13.08M 87.82M 34.33M 437M 34.55M 33.79M 1.45B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-13.79%
1 week+113.31%
Current month+199.27%
1 month+60.26%
3 months-16.39%
6 months-7.41%
Current year-72.07%
1 week 0.03
Extreme 0.0326
0.14
1 month 0.03
Extreme 0.0326
0.14
Current year 0.03
Extreme 0.0326
0.47
1 year 0.03
Extreme 0.0326
6.66
3 years 0.03
Extreme 0.0326
74.8
5 years 0.03
Extreme 0.0326
152.5
10 years 0.03
Extreme 0.0326
160.4
Manager TitleAgeSince
Chief Executive Officer 67 18/06/2009
Director of Finance/CFO 66 05/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 18/06/2009
Director/Board Member 70 31/05/2009
Director/Board Member 56 19/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25 Free

Chief Executive Officer

500,000 1.2036%
17/02/25 Free

Chief Operating Officer

500,000 1.6737%
14/02/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+113.31%-95.97%-99.83% 581K
+1.79%+9.11%+101.50%+439.38% 38.72B
+1.60%-0.60%+18.38%+45.12% 24.87B
-0.91%-3.74%-20.88%-35.77% 7.55B
+3.62%+9.49%+24.12%+108.49% 5.25B
-0.58%+4.66%+21.90%+60.80% 3.33B
+2.84%+21.57%+187.30%+2.32% 2.04B
+4.48%+14.58%-34.56%+893.00% 2.01B
+0.51%+4.14%-10.29%-59.58% 1.89B
+3.06%+2.52%+22.31%+9.72% 1.85B
Average +0.25%+6.22%+21.38%+136.37% 8.75B
Weighted average by Cap. +1.60%+5.60%+54.42%+232.51%

Financials

2024 2025
Net sales 6.77M 5.88M 5.48M 5.03M 9.52M 644M 9.63M 64.62M 25.26M 322M 25.42M 24.87M 1.07B 4.34M 3.77M 3.52M 3.23M 6.11M 413M 6.18M 41.47M 16.21M 207M 16.32M 15.96M 685M
Net income -53.36M -46.34M -43.2M -39.69M -75.06M -5.08B -75.88M -509M -199M -2.54B -200M -196M -8.41B -14.74M -12.8M -11.94M -10.96M -20.74M -1.4B -20.96M -141M -55.01M -701M -55.36M -54.15M -2.32B
Net Debt 23.9M 20.75M 19.34M 17.77M 33.61M 2.27B 33.98M 228M 89.16M 1.14B 89.73M 87.77M 3.76B 8.53M 7.4M 6.9M 6.34M 12M 811M 12.13M 81.4M 31.82M 406M 32.03M 31.32M 1.34B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
04/08/26 US$0.0480 +15.80% 18,898
03/08/26 US$0.0415 -0.76% 20,473
31/07/26 US$0.0418 -16.46% 218,908
30/07/26 US$0.0500 -16.67% 159,558
29/07/26 US$0.0600 +2.39% 11,692

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock